Overview:
Research in Dr. Alnouti's laboratory is involved in the multidisciplinary area of drug metabolism and pharmacokinetics (DMPK). His research focuses on the application of Bioanalytical Chemistry, in vitro and in vivo animal models to support ADME (absorption, distribution, metabolism, and excretion) and pharmacokinetic (PK) studies. This is a technique-driven enterprise; therefore expertise in liquid chromatography-mass spectrometry (LC-MS) is heavily used in our research.
Another area of interest in Dr. Alnouti's laboratory is the discovery of biomarkers for hepato-biliary diseases and drug-induced liver injury (DILI) based on bile acid metabolism.
Projects:
I. Characterization of the pharmacokinetic (PK) and ADME profiles of novel nano-delivery systems of anti-HIV drugs.
II. The development of a novel in vitro system to predict the lymphatic penetration of anti-HIV drugs.
III. Provide in vitro and in vivo DMPK support for drug discovery in several therapeutic areas.
IV. The role of bile acid (BA) sulfation in hepatobiliary diseases.
V. Species differences of BA metabolism and the role of BA homeostasis in drug-induced liver injury (DILI).
VI. The role of BA in type-2 diabetes mellitus remission after bariatric surgery.
V. Species differences of BA metabolism and the role of BA homeostasis in drug-induced liver injury (DILI).
VI. The role of BA in type-2 diabetes mellitus remission after bariatric surgery.